Table 2.

Whom to screen.

Lp(a) should be measured once in all subjects at intermediate or high risk of CVD/CHD who present with one of the following:

(i) Premature CVD

(ii) Recurrent CVD despite statin treatment

(iii) Familial hypercholesterolemia

(iv) Strong family history of premature CVD and/or elevated Lp(a) ≥500 mg/L

(v) Recurrent CVD despite optimal lipid-lowering treatment

(vi) ≥5% 10-year risk of fetal CVD according to European guidelines

(vii) ≥10% 10-year risk of fetal CVD according to US guidelines

(viii) 10–19% Framingham risk according to the 2012 Canadian Cardiovascular Society recommendations

Repeat measurement is only necessary if treatment for high Lp(a) levels is initiated in order to evaluate therapeutic response

This table was adopted from [194].